Jazz Pharmaceuticals plc Financials

Market Capitalization $7.40 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	17.37
Forward PE	5.68
Price to Sales TTM	$1.85
Price to Book MRQ	$1.77
Enterprise to Revenue	2.75
Enterprise to EBITDA	7.24

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	11.60%
Operating Margin	24.67%
Return on Assets TTM	4.62%
Return on Equity TTM	12.09%

Income Statement

Revenue TTM	$3,992,711,936
Revenue per Share TTM	$64.04
Quarterly Revenue Growth	8.50%
Gross Profit TTM	$3,698,041,088
EBITDA	$1,327,208,000
Net Income to Common TTM	$463,159,008
Diluted EPS TTM	$7.05
Quarterly Earnings Growth YoY	46.50%

Balance Sheet

Total Cash MRQ	$2,618,148,096
Total Cash per Share MRQ	$43.31
Total Debt MRQ	$
Total Debt to Equity MRQ	148.75
Current Ratio MRQ	4.26
Book Value per Share MRQ	$69.01

Cash Flow

Operating Cash Flow TTM	$1,164,667,008
Levered Free Cash Flow TTM	$1,049,404,480

JAZZ Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	60,454,600
Float Shares	58,667,554
Avg 10 Volume	452,020
Avg 30 Volume	None
Shares Short	3,847,078
Short Ratio	6.49
Short % of Shares	8.48%
% Held by Insiders	2.94%
% Held by Institutions	98.82%

Stock Price Summary

Beta	0.57
Fifty Two Week Low	$99.06
Fifty Two Week High	$134.17
Fifty Two Week Change	-4.38%
Day 50 MA	$122.75
Day 200 MA	$113.03

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date